CD59 signaling and membrane pores drive Syk-dependent erythrocyte necroptosis

TJ LaRocca¹,⁴, EA Stivison², T Mal-Sarkar¹, TA Hooven¹, EA Hod³, SL Spitalnik³ and AJ Ratner*¹

Mature erythrocytes (red blood cells (RBCs)) undergo the programmed cell death (PCD) pathway of necroptosis in response to bacterial pore-forming toxins (PFTs) that target human CD59 (hCD59) but not hCD59-independent PFTs. Here, we investigate the biochemical mechanism of RBC necroptosis with a focus on the mechanism of induction and the minimal requirements for such RBC death. Binding or crosslinking of the hCD59 receptor led to Syk-dependent induction of vesiculated morphology (echinocytes) that was associated with phosphorylation of Band 3 and was required for Fas ligand (FasL) release. FasL-dependent phosphorylation of receptor-interacting protein kinase 1 (RIP1) in combination with plasma membrane pore formation was required for execution of RBC necroptosis. RIP1 phosphorylation led to the phosphorylation of RIP3, which was also critical for RBC necroptosis. Notably, RBC necroptosis was mediated by FasL and not by other candidate inducers, including tumor necrosis factor alpha (TNF-α) and TNF-related apoptosis-inducing ligand (TRAIL). Other types of RBC damage, such as eryptotic damage, failed to induce necroptosis when combined with hCD59 crosslinking. This work sheds light on the requirements for this recently discovered PCD in RBCs and provides a clear picture of the biochemical mechanism of induction of RBC necroptosis.

Cell Death and Disease (2015) 6, e1773; doi:10.1038/cddis.2015.135; published online 28 May 2015

Recently, we demonstrated that bacterial pore-forming toxins (PFTs) that target human CD59 (hCD59) induce programmed necrosis (necroptosis) in primary erythrocytes (red blood cells, RBCs). This observation was striking, as RBC lack nuclei and mitochondria. Nonetheless, RBC necroptosis proceeded in a manner similar to that observed in nucleated cells, requiring Fas and Fas ligand (Fas/FasL), mixed lineage kinase domain-like protein, and the phosphorylation of receptor-interacting protein kinase 1 (RIP1) kinase. RBC necroptosis was antagonized by caspase-6 and was associated with necosome formation and conserved necroptosis effector pathways including acid sphingomyelinase-dependent ceramide formation, NADPH oxidase/iron-dependent reactive oxygen species formation, and glycolytic formation of advanced glycation end products (AGEs). While RBC necroptosis shared many molecular steps with canonical necroptosis pathways, it was distinct from eryptosis, a RBC-specific programmed cell death (PCD) that functions as a trigger for RBC clearance by macrophages.

Proteins that induce plasma membrane pores are a common biological theme and may be pathogen produced, such as bacterial PFTs, or host produced, such as the membrane attack complex (MAC) of the complement system. Pore formation may kill cells through osmotic lysis or may activate target cell signaling pathways including proinflammatory, membrane repair, and PCD modules. However, the specific mechanisms linking bacterial PFTs to RBC necroptosis have not been described.

In this study, we sought to understand the mechanism of induction of RBC necroptosis by bacterial PFTs and the minimal requirements for such death in these target cells. In particular, we show that hCD59 signaling, induced by receptor crosslinking, results in Syk-dependent phosphorylation of Band 3 leading to vesicle (echinocyte) formation and release of FasL. Released FasL induces the phosphorylation of RIP1, which in turn leads to RIP3 phosphorylation. The FasL-dependent phosphorylation of RIP1/RIP3 produces RBC death by necroptosis only when combined with functional pore formation. The ability for necroptosis to proceed in RBCs differs depends on the size and nature of membrane pores. Additionally, we show that RBC necroptosis is mediated only by FasL and not by other known necroptotic mediators/stimuli, including tumor necrosis factor alpha (TNF-α) and TNF-related apoptosis-inducing ligand (TRAIL).

¹Department of Pediatrics, Columbia University, New York, NY, USA; ²Institute of Human Nutrition, Columbia University, New York, NY, USA and ³Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.

*Corresponding author: AJ Ratner, Department of Pediatrics, Columbia University, 650 West 168th Street (BB 4-443), New York, 10032 NY, USA. Tel: +1 212 305 9807; Fax: +1 212 342 5218; E-mail: ar127@columbia.edu

Current address: Department of Basic and Social Sciences, Albany College of Pharmacy and Health Sciences, Albany, NY, USA.

Abbreviations: AGEs, advanced glycation end products; ALN, aracothylinosin; aSMase, acid sphingomyelinase; CDC, cholesterol-dependent cytolyisin; CL-CD59, crosslinked CD59; CL-D4, crosslinked VLY domain 4; DPA, desipramine hydrochloride; FasL, Fas Ligand; GFP, green fluorescent protein; hCD59, human CD59; ILY, intermediolin; LLO, listeriolysin O; mAb, monoclonal antibody; MAC, membrane attack complex; MLKL, mixed lineage kinase domain-like; NOX, NADPH oxidase; nec-1, necrostatin-1; pAb, polyclonal antibody; PCD, programmed cell death; PFTs, pore-forming toxins; PLV, pneumolysin; PLV-D4, D4 domain; p-RIP1, phosphorylated RIP1; p-RIP3, phosphorylated RIP3; p-Syk, phosphorylated Syk; RBCs, red blood cells; RIP, receptor-interacting protein kinase; ROS, reactive oxygen species; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand; VLY, vaginolysin; VLY-D4, D4 domain

Received 7.11.14; revised 11.3.15; accepted 20.4.15; Edited by H-U Simon
Results

RBC necroptosis induced by hCD59-specific PFTs is mediated by FasL but not by other known mediators/stimuli of necroptosis. We previously demonstrated that RBC necroptosis, induced by the hCD59-specific PFTs vaginolysin (VLY) and intermedilysin (ILY), is dependent on Fas-FasL signaling, as a monoclonal antibody targeting FasL (mAb NOK-1) significantly inhibited RBC death. 1 Recombinant FasL (rFasL) enhances RBC death by near sublytic quantities of PFTs in a necrostatin-1-inhibitable manner (Figure 1a). The hCD59-specific PFTs, VLY and ILY, induce FasL-dependent phosphorylation of RIP1 in RBCs, 1 and addition of rFasL (but not rTNF-α or rTRAIL) to RBCs induces the phosphorylation of RIP1 (Figure 1b). Due to the fact that rFasL is sufficient to trigger RIP1 phosphorylation, its inclusion allows hCD59-independent PFTs, pneumolysin (PLY) and Staphylococcus aureus alpha toxin (A-tox), to induce necroptosis in RBCs (Figure 1a). 1

As FasL triggers necroptosis in some nucleated cells, 5–7 we asked whether two other defined stimuli of necroptosis, TNF-α and TRAIL, 6,7 have a role in this PCD in RBCs. In contrast to rFasL, addition of rTNF-α or rTRAIL to RBCs failed to induce RIP1 phosphorylation (Figure 1b). Additionally, while neutralization of FasL with a mAb inhibits RBC necroptosis by VLY and ILY, 1 similar neutralization of TNF-α or TRAIL had no effect on necroptosis by these hCD59-specific PFTs (Figures 1c and e). Moreover, while the addition of exogenous rFasL endows PFTs with the ability to induce RBC necroptosis, regardless of intrinsic hCD59 specificity, similar addition of rTNF-α or rTRAIL had no effect on RBC death (Figures 1d and f). These results indicate that FasL is a critical mediator of RBC necroptosis.

Binding or crosslinking of hCD59 leads to phosphorylation of RIP1 in human RBCs. hCD59-specific PFTs (VLY and ILY) induce RBC necroptosis while hCD59-independent PFTs do not, 1 but it is not known whether hCD59 ligation itself induces necroptosis signaling pathways. Treatment of RBCs with either an hCD59-specific mAb or a histidine-tagged version of the VLY binding domain (VLYD4) triggered RIP1 phosphorylation in RBCs (Figure 2a). Cross-linking of the hCD59-binding reagents with an anti-mouse IgG pAb (for the mAb) or an anti-His mAb (for VLYD4) resulted in more robust
RIP1 phosphorylation (Figure 2a). Thus, signaling through hCD59 is sufficient to induce RIP1 phosphorylation in human RBC. The hCD59-specific PFT VLY induces RIP1 phosphorylation in RBCs, while the related but non-hCD59-specific PLY does not. To determine whether toxin-induced RIP1 phosphorylation depends entirely on PFT binding to hCD59, we generated binding domain-swapped mutant versions of these PFTs (Figure 2b). When VLY was modified with the binding domain of PLY (VLY-PLYD4), it did not induce RIP1 phosphorylation (Figure 2b). On the other hand, when PLY was modified with the binding domain of VLY (PLY-PLYD4) such that it was capable of binding hCD59, it did result in RIP1 phosphorylation (Figure 2b). The phosphorylation of RIP1 is specific to CD59 signaling in RBCs as crosslinking of a related membrane protein, CD55, did not result in RIP1 phosphorylation (Figure 2b). Likewise, when we crosslinked the binding domain of PLY (PLYD4), which does not bind hCD59, there was no phosphorylation of RIP1 (Figure 2b). These results demonstrate that PFT-mediated RIP1 phosphorylation depends on hCD59 ligation in RBCs.

The induction of RIP1 phosphorylation by mAb crosslinked hCD59 (CL-CD59) in RBCs was retained when combined with the hCD59-independent PFTs, PLY or A-tox (Figure 2c), or with two distinct inducers of eryptosis, hyperosmotic stress or excess calcium (Figure 2d). In addition, phosphorylation of RIP1 induced by hCD59 signaling via hCD59-specific mAb or VLYD4 was inhibited by both nec-1 and mAb against FasL (Figure 2e).

Crosslinking of hCD59 as well as hCD59-specific PFTs induces the phosphorylation of RIP3, which is required for RBC necroptosis. Similar to the phosphorylation of RIP1 (Figure 2), RIP3, which is also critical for necroptosis, is phosphorylated in response to crosslinking of hCD59 or hCD59-specific PFTs, VLY and ILY in RBCs (Figure 3a).
The hemolysis assay is the results of three experiments following 1 h incubation with GSK treatment times for IPs were 1 h. Time points for hemolysis assays were 30 min by CL-CD59 or VLY, are prevented by inhibition of RIP3 with GSK in the absence of PFTs. The induction of RBC necroptosis by hCD59 is consistent with necroosome formation in RBC necroptosis.1 hCD59-independent PFTs, PLY and A-tox, did not induce RIP3 phosphorylation. The phosphorylation of RIP3 was prevented by the recently characterized inhibitor of RIP3, GSK'872,6 or by RIP1 inhibition with nec-1 (Figure 3b). That nec-1 prevents RIP3 phosphorylation indicates that this kinase is phosphorylated due to the action of RIP1 as is the case in nucleated cells.7 Inhibition of RIP3 with GSK'872 also reduced RBC death by VLY and ILY but not by PLY or A-tox. Treatment times for IPs were 1 h. Time points for hemolysis assays were 30 min following 1 h incubation with GSK'872. Error bars in the hemolysis assay represent standard deviation. The hemolysis assay is the results of three experiments.

Figure 3  hCD59 signaling leads to RIP1-dependent phosphorylation of RIP3, which is critical for RBC necroptosis. (a) RIP3 IPs showing the phosphorylation of RIP3 (p-RIP3) in response to the hCD59-specific PFTs, VLY and ILY but not by the hCD59-independent PFTs, PLY and A-tox. Crosslinking of hCD59 with mAbs (CL-CD59) induces p-RIP3 in the absence of PFTs. (b) IPs showing that p-RIP3, induced by CL-CD59 or VLY, are prevented by inhibition of RIP3 with GSK'872 (2 μM) or inhibition of RIP1 with nec-1 (50 μM). (c) Hemolysis assay showing that inhibition of RIP3 with GSK'872 (2 μM) reduces RBC death by VLY and ILY but not by PLY or A-tox. Treatment times for IPs were 1 h. Time points for hemolysis assays were 30 min following 1 h incubation with GSK'872. Error bars in the hemolysis assay represent standard deviation. The hemolysis assay is the results of three experiments.

is consistent with necroosome formation in RBC necroptosis.1 hCD59-independent PFTs, PLY and A-tox, did not induce RIP3 phosphorylation. The phosphorylation of RIP3 was prevented by the recently characterized inhibitor of RIP3, GSK'872,6 or by RIP1 inhibition with nec-1 (Figure 3b). That nec-1 prevents RIP3 phosphorylation indicates that this kinase is phosphorylated due to the action of RIP1 as is the case in nucleated cells.7 Inhibition of RIP3 with GSK'872 also reduced RBC death by VLY and ILY but not by the hCD59-independent PFTs, PLY, and A-tox, demonstrating a critical role for RIP3 in the necrotic death of RBCs (Figure 3c).

Binding or crosslinking of hCD59 leads to necroptosis of RBCs when combined with PLY. Although crosslinking of hCD59 with antibody or VLYD4 induces RIP1 phosphorylation, it is not sufficient to induce necrototic death in RBCs (Figure 4a).

The induction of RBC necroptosis by hCD59 crosslinking and pore formation depends on the size and composition of the membrane pore. As hCD59 binding/crosslinking led to RBC necroptosis when combined with PLY, we hypothesized that hCD59 signaling might induce RBC necroptosis when combined with any agent that forms membrane pores. Therefore, we examined the effect of CL-CD59 on RBC death caused by the cholesterol-dependent cytolsins arcanolysin and listeriolysin O, the complement MAC, the cholesterol-independent PFT S. aureus a-toxin (A-tox), or the polypeptide PFT of Streptococcus agalactiae β-hemolysin/cytolysin (Figure 5). When CL-CD59 was combined with the cholesterol-dependent cytolsins, ALN or LLO, or the MAC it resulted in a level of RBC necroptosis similar to CL-CD59 with PLY (Figures 5a and c). However, when combined with A-tox, which forms pores of 1–2 nm in diameter, in contrast to the large pores (≥10 nm) formed by cholesterol-dependent cytolsins9 and the MAC,10 CL-CD59 induced a much lower level of necroptosis in RBCs (Figure 5d). When combined with the non-protein PFT β-hemolysin/cytolysin, CL-CD59 failed to induce RBC necroptosis (Figure 5e). The pore size for β-hemolysin/cytolysin has not been formally determined but is thought to be large.11 Thus, RBC necroptosis induced by CL-CD59 combined with PFTs depends on pore size and perhaps nature (protein versus non-protein). RBC necroptosis induced by hCD59 signaling appears specific to damage by membrane pore formation, as CL-CD59 did not enhance death via eryptosis (Figure 5f).

Pore formation is critical for the induction of RBC necroptosis by hCD59 signaling. PFTs may activate host cell signaling pathways via pore-dependent or -independent mechanisms.4 We tested whether RBC necroptosis triggered by CL-CD59 and PFTs required functional pores. RBC death caused by the hCD59-specific PFTs, VLY and ILY, was abolished by dextran osmoprotection (Figures 6a and b). Additionally, mutant versions of PLY and A-tox that are capable of binding but are defective in membrane pore formation (PdB and A-tox toxoid, respectively)8–10 did not induce RBC death with or without CL-CD59 (Figure 6c). Moreover, RBC necroptosis induced by the combination of CL-CD59 with PLY, ALN, LLO, or A-tox was completely inhibited under osmoprotective conditions (Figures 6d and g). These results collectively demonstrate that functional membrane pore formation is required for hCD59-induced necroptosis in RBCs.
Figure 4 The combination of hCD59 crosslinking and PLY induces RBC necroptosis. (a) Hemolysis assay showing that mAb binding or crosslinking of hCD59 (CD59) or hCD59 binding or crosslinking with the binding domain of VLY fused to GFP (VLYD4-GFP) does not induce death of RBCs. When hCD59 is bound or crosslinked with (b) mAb against hCD59 or (c) VLYD4-GFP it results in an enhancement of RBC death by the hCD59-independent PLY (0.2 HU). Enhanced RBC death by PLY in the presence of crosslinked hCD59 is prevented by (d) the RIP1 inhibitor, nec-1 (50 μM) or (e) the FasL neutralizing mAb, NOK-1 (1 μg/ml). Enhanced RBC death by PLY in the presence of crosslinked hCD59 is reduced by inhibitors of downstream effector pathways in RBC necroptosis including (f) inhibition of ceramide formation with acid sphingomyelinase (aSMase) inhibitor desipramine (DPA, 20 μM), (g) inhibition of reactive oxygen species (ROS) with the iron chelator 2,2-bipyridyl (bipyridyl, 100 μM) or (h) inhibition of AGES with pyridoxamine (1 mM). Time points for hemolysis assays were 30 min. When pharmacological or mAb inhibitors were used RBCs were treated for 1 h before the addition of stimuli. IgG = irrelevant IgG control, CD55 = mAb against hCD55, GFP = addition of rGFP alone. Error bars in hemolysis assays represent standard deviation. All hemolysis assays are the results of three independent experiments. Two-way ANOVA with Bonferroni posttest, ***P < 0.001.
**CD59 drives erythrocyte necroptosis**

**TJ LaRocca et al**

**RBC necroptosis is associated with echinocyte transformation.** We next examined the morphology of RBCs exposed to hCD59-specific PFTs or to mAb-based hCD59 crosslinking (Figure 7). When exposed to VLY or ILY, which induce RBC necroptosis, RBCs underwent a morphological transformation to echinocytes (Figure 7). Echinocytes are a phenotype of RBCs that actively form and release vesicles and can be induced by a number of different forms of stress. Echinocyte transformation was not observed in response to A-tox, which do not induce RBC necroptosis. The basis for echinocyte transformation of RBCs during necroptosis depended on hCD59 binding, as VLY-PLYD4 did not induce echinocyte transformation while PLY-VLYD4 did (Figure 7). hCD59 crosslinking alone was sufficient to induce echinocyte transformation (Figure 7).

**Phosphorylation of Band 3 by Syk kinase leads to FasL release, echinocyte transformation, and RBC necroptosis.** Echinocyte formation in RBCs is mediated by Syk kinase-dependent phosphorylation of the integral membrane protein Band 3. The phosphorylation of Y21 of Band 3 by Syk disrupts the binding of this protein to the adaptor protein Ankyrin, thereby severing the anchoring of the RBC membrane to the spectrin cytoskeleton. Due to this disruption, membrane vesiculation proceeds in RBCs resulting in the appearance of the echinocyte morphology. As echinocyte formation was associated with RBC necroptosis (Figure 7) we asked whether Syk-dependent Band 3 phosphorylation occurred during this PCD. Indeed, phosphorylated Band 3 was observed in RBCs in response to the necroptosis-inducing hCD59-specific PFTs, VLY and ILY, but...
not in response to the hCD59-independent PLY and A-tox (Figure 8a). Furthermore, hCD59 signaling alone was sufficient to induce p-Band 3 as observed by mAb cross-linking of hCD59 (Figure 7a). Phosphorylation of Band 3 was also dependent on Syk, consistent with the molecular mechanism of echinocyte formation in RBCs (Figure 8b).

As Syk-dependent echinocyte formation is associated with RBC necroptosis, we considered a potential role for RBC vesiculation in this PCD pathway. FasL-dependent death in other cell types requires the release of FasL in membrane vesicles, which is followed by FasL binding to its receptor, Fas.7,17–20 We observed FasL release from RBCs in response to sub-lytic quantities of VLY and ILY but not PLY or A-tox (Figures 8c and d). Crosslinking of hCD59 alone, which does not induce RBC death (Figure 4a), also resulted in the release of FasL from RBCs (Figures 8c and d). The release of FasL from RBCs in response to these necrotic stimuli was dependent on Syk, suggesting that RBC vesiculation/echinocyte formation is the basis for FasL release during RBC necroptosis (Figures 8c and d). This is necessary for RBC necroptosis to proceed as the inhibition of Syk also prevented the phosphorylation of RIP1 and RIP3 induced by hCD59-specific PFTs or CL-CD59 (Figures 8e and f). As predicted, RIP1 and RIP3 phosphorylation was downstream of Syk-dependent Band 3 phosphorylation as nec-1 had no effect on this event (Figure 8g).

Syk inhibition on RBCs prevented CL-CD59-induced echinocyte transformation, but nec-1 had no effect (Figure 8h) supporting the concept that Syk-dependent Band 3 phosphorylation leads to vesiculation in RBC necroptosis and that RIP1 and RIP3 phosphorylation are downstream of this event. Syk activity was required for necrotic death of
RBCs as its inhibition resulted in a decrease of RBC death caused by VLY and ILY while having no effect on RBC death by PLY (Figures 8i and k). Inhibition of Syk also reduced RBC necroptosis caused by the combination of CL-CD59 and PLY (Figure 8l). Src family kinases interact with CD59 and phosphorylate cytosolic targets such as Syk in response to extracellular signals, which may subsequently drive vesiculation. This is indeed the case in the induction of RBC necroptosis as inhibition of Src family kinases prevented the phosphorylation of Syk induced by VLY, ILY, or CL-CD59 (Figure 8m). The hCD59-independent PFTs, PLY and A-tox, did not induce phosphorylation of Syk, consistent with the results of Band 3 phosphorylation and echinocyte formation. These results suggest that hCD59 signaling activates Src family kinases, which lead to Syk-dependent vesiculation that is required for FasL-dependent RBC necroptosis.

Discussion

**Minimal requirements for RBC necroptosis.** Our biochemical analysis of RBC necroptosis has allowed us to determine its minimal requirements. The combination of phosphorylated RIP1/RIP3 and a functional membrane pore results in necroptosis of RBCs. RIP1 phosphorylation can be induced by rFasL (Figure 1c) or by hCD59 signaling (mediated by endogenous FasL) in RBCs (Figure 2e). Additionally, hCD59 signaling leads to RIP3 phosphorylation mediated by RIP1 (Figures 3a and b). Despite the fact that these stimuli induce RIP1/RIP3 phosphorylation in RBCs they were not sufficient to cause death (Figures 1b and 4a). However, when combined with the addition of PFTs to RBCs these stimuli did induce necroptosis (Figures 1b, 4d, h, 5a, and d). Osmotic protection and experiments with pore-deficient toxoids (Figure 6) supported the hypothesis that the combination of phosphorylated RIP1/RIP3 and a functional membrane pore are minimally required for RBC necroptosis. Membrane pore-induced damage appears to be specifically required for RBC necroptosis, as hCD59 crosslinking had no effect on RBC death by eryptosis (Figure 5f).

Although functional pore formation is required for RBC necroptosis, the ability to stimulate necroptosis appears to depend on pore size and possibly toxin composition. hCD59 crosslinking stimulated robust necroptosis when combined with toxins that form large, protein-based pores. In contrast, hCD59 crosslinking primed RBC necroptosis to a much weaker extent when combined with A-tox (Figure 5d), which forms smaller pores, and not at all with the polyene β-hemolysin (Figure 5e). This suggests that RBC necroptosis may be a specific response to protein-based membrane pores.

**Biochemical induction of hCD59-induced necroptosis in RBCs.** Our findings have shed light on the mechanism of...
hCD59-induced RBC necroptosis providing a fundamental understanding of RBC necroptosis caused by hCD59-specific PFTs (Figure 9). The process of RBC necroptosis begins with ligation of the hCD59 receptor. Crosslinking of hCD59 alone leads to vesicle formation in RBCs, transforming these cells into echinocytes (Figure 7). This begins as hCD59 signaling that leads to phosphorylation/activation of Syk via Src family kinases (Figure 8m). The induction of membrane vesiculation in RBCs downstream of hCD59/Src signaling is mediated by Syk-dependent phosphorylation of the integral membrane protein, Band 3 (Figures 8a, b, and 8h). The Syk-dependent formation of vesicles is the basis for the release of FasL from RBCs (Figures 8c and d). Following release from RBCs due to Syk-dependent vesiculation, FasL is free to bind its cognate receptor, Fas. The ligation of FasL with Fas leads to the phosphorylation of RIP1 (Figures 1b and 2e), which is
critical for necroptosis in RBCs and other cell types.\(^1\)\(^,\)\(^7\) It is clear that the interaction of FasL with Fas is upstream of RIP1 phosphorylation as neutralization of FasL prevents this phosphorylation downstream of hCD59 signaling (Figure 2e). Additionally, we have confirmed that FasL release is downstream of membrane vesiculation/echinocyte formation as inhibition of Syk prevents the release of FasL and the phosphorylation of RIP1 (Figures 8c and e). Moreover, FasL release occurs in the absence of RBC death, suggesting that this event occurs before the induction of necroptotic death (Figures 8c and d). The RIP1 inhibitor, nec-1, had no effect on the phosphorylation of Band 3 (Figure 8g) providing further confirmation that membrane vesiculation/echinocyte formation is upstream of RIP1 phosphorylation in RBC necroptosis. FasL-dependent RIP1 phosphorylation subsequently results in the phosphorylation of RIP3, which is required for RBC necroptosis (Figure 3). While hCD59 signaling alone causes FasL-dependent RIP1/RIP3 phosphorylation via Syk-dependent membrane vesiculation in RBCs, this is not sufficient to promote death by necroptosis (Figure 4a). Functional pore formation in the RBC membrane was shown to be necessary for necroptosis in these cells (Figure 6). This leads to the conclusion that while RIP1/RIP3 phosphorylation and functional pore formation are each necessary for RBC necroptosis they are sufficient to promote this PCD only in combination.

Figure 9 Proposed mechanism for RBC necroptosis. (a) RBCs contain CD59, Fas, FasL, and the transmembrane protein Band 3 in their membrane. Band 3 anchors the membrane to the spectrin cytoskeleton via the adaptor protein Ankyrin. Within the RBC cytoplasm are RIP1 and RIP3 kinases. (b) RBC necroptosis is initiated through CD59 crosslinking/signaling, which may be caused by the binding of hCD59-specific PFT monomers (pictured). CD59 signaling leads to the phosphorylation of Syk kinase through the action of Src family kinases. Following activation by CD59/Src kinases, Syk phosphorylates Band 3. (c) Syk-dependent Band 3 phosphorylation disrupts anchoring of the RBC membrane to the spectrin cytoskeleton resulting in vesiculation/echinocyte formation. (d) FasL is released due to Syk-dependent vesiculation/echinocyte formation and subsequently binds its cognate receptor, Fas. Fas receptor signaling, following ligation of FasL, leads to the phosphorylation of RIP1 which in turn phosphorylates RIP3, but is not sufficient to induce necroptotic death of RBCs. (e) Creation of a membrane pore by PFTs combined with the phosphorylation of RIP1/RIP3 leads to RBC necroptosis and the death of the RBC.
Although Syk-dependent membrane vesicle production/echinocyte formation is not specific to RBC necroptosis, our findings indicate that this event is critical for necroptosis to proceed. This is evident as the inhibition of Syk resulted in a decrease in RBC death caused by the necroptosis-inducing hCD59-specific PFTs, VLY and ILY while having no effect on death by PLY, which does not induce RBC necroptosis (Figures 8i and k). Further evidence of the requirement of Syk-dependent vesiculation/echinocyte formation for RBC necroptosis was shown as Syk inhibition completely prevented this PCD induced by the combination of crosslinked hCD59 and PLY (Figure 8l).

In nucleated cell types, necroptosis is mediated by one of three ligands of the TNF superfamily, TNF-α, FasL, or TRAIL.5—7 Our results suggest that in RBCs, necroptosis is mediated only by FasL. This is evident as addition of rFasL to RBCs resulted in the phosphorylation of RIP1 while addition of rTNF-α or rTRAIL did not (Figure 1b). Furthermore, while rFasL endows bacterial PFTs with the ability to induce RBC necroptosis regardless of intrinsic hCD59 specificity (Figure 1a), rTNF-α and rTRAIL do not (Figures 1d and f). It is also clear that RBC necroptosis induced by hCD59-specific PFTs is specifically mediated by endogenous FasL1 and not TNF-α or TRAIL (Figures 1c and e).

Potential relevance of RBC necroptosis to pathological conditions. That the combination of phosphorylated RIP1/RIP3 (induced by FasL alone or hCD59 signaling) and certain PFTs results in necroptosis in RBCs (Figures 1a, 4d, h, 5a, and d) may be of relevance to pathologic situations in vivo. In the context of infection by an organism such as S. pneumoniae, FasL has been shown to be present at high levels in vivo8,9 and in vitro. As infection with S. pneumoniae can progress to bacteremia10 it is possible that the combination of circulating FasL and PLY leads to RBC necroptosis as a component of systemic infection. Moreover, as the natural function of hCD59 is to prevent the formation of the MAC through binding of complement components C8 and C9, we speculate that RBC necroptosis may occur during situations of autoimmune complement attack. In a situation such as this we would expect C8/C9 to be bound to hCD59 on RBCs, eliciting signal transduction by this receptor. This combined with formation of a functional MAC may produce RBC necroptosis as is the case for CL-CD59 and the MAC (Figure 5c). This idea is supported by the evidence that hCD59 signaling induced by C8/C9 mimicks the signal transduction caused by mAb crosslinking of this receptor in vitro.26

Materials and Methods

Human RBCs. Primary human RBCs were obtained from healthy volunteers under a protocol approved by the Columbia University Institutional Review Board.

Receptor crosslinking. Crosslinking of hCD59 was achieved with anti-CD59 mAb MEM-43 (1 μg/ml, ThermoScientific, Waltham, MA, USA) and goat anti-mouse IgG (1:100, Jackson ImmunoResearch, West Grove, PA, USA). hCD59 crosslinking was also achieved with a GFP and His-tagged version of the VLY binding domain (10 μg/ml, VLYD4-GFP) and mouse anti-His mAb (1:100, Sigma-Aldrich, St. Louis, MO, USA) or chicken anti-GFP pAb (1:100, EMD Millipore, Billerica, MA, USA). hCD59 crosslinking was achieved with anti-CD59 mAb (10 μg/ml, ThermoScientific) and goat anti-mouse IgG (1:50, Jackson ImmunoResearch). As negative controls, His-tagged PLYD4 (10 μg/ml) and anti-His mAb (1:50, Sigma-Aldrich) or GSP and chicken anti-GFP pAb (1:50, EMD Millipore) was added to RBCs. For hemolysis assays, receptor crosslinking was performed concurrently with PFT treatment. For immunoprecipitations (IPs), receptor crosslinking was performed at 37 °C for 30 min followed by the IP procedure.

Pharmacological and mAb-based inhibitors. For neutralization of FasL, TNF-α, or TRAIL, mAbs NOK-1 (Becton Dickenson, Franklin Lakes, NJ, USA), I92/13 (Axxora, Farmingdale, NY, USA, or RIK-2 (Becton Dickenson), respectively, were used at 1 μg/ml. Inhibition of Rip1 kinase was achieved with 50 μM necrostatin-1 (EMD Millipore). Inhibition of Rip3 was achieved with 2 μM GSK872 (EMD Millipore). Inhibition of acid sphingomyelinase was achieved with 20 μM desamine hydrochloride (DPA, Tocris Bioscience, Bristol, UK). Iron chelation was achieved with 100 μM 2,2-bipyridyl (Alfa Aesar, Ward Hill, MA, USA). Inhibition of AGE formation was achieved with 1 μM pyridoxamine (Acrors Organics, Waltham, MA, USA). For inhibition of Syk kinase, Syk kinase inhibitor IV, Bay 61-3606 (EMD Millipore) was used at 2 μM. Inhibition of Src family kinases was achieved with 1 μM PP1 (EMD Millipore). Osmotic protection was performed with 10% dextan (50,000 MW) in DPBS.

Hemolysis assays. Recombinant PFTs were expressed and purified as previously described.11,27,28 β-Hemolysis was extracted from S. agalactiae according to the method of Liu et al.29 Hemolysis assays were performed in DPBS at 37 °C for 30 min with PFTs at the indicated hemolytic units (HU). 1 HU is defined as the concentration at which a PFT causes 50% hemolysis.1 When mAb or pharmacological inhibitors were used they were incubated with RBCs for 1 h at 37 °C before PFT addition. rFasL (Super Fas ligand, Enzo Life Sciences, Farmingdale, NY, USA), rTNF-α (Invitrogen, Waltham, MA, USA), or rTRAIL (Killer TRAIL, Enzo Life Sciences) was added to RBCs at the same time as PFTs. Receptor crosslinking was performed concurrently with PFT treatment. Hemolysis was measured by relative quantification of hemoglobin release in a spectrophotometer at 415 nm.

Hemolysis by the MAC was induced by the classical complement pathway. RBCs were treated with rabbit anti-RBC mAb (1:100, Rockland Immunochemicals, Limerick, PA, USA) for 1 h at 37 °C followed by treatment with several dilutions of rabbit complement serum ( Fitzgerald, Acton, MA, USA) in DPBS.

Immunoprecipitations. IPs for RIP1 and RIP3 were performed on RBC sonicates with 10 μg anti-RIP mAb (clone G322-2, Becton Dickenson) for RIP1 or 10 μg anti-RIP3 mAb (clone RIPP3y, ProSci, Poway, CA, USA) at 4 °C overnight following pre-clearing. Protein G Plus Agarose beads (100 μl, Pierce, Rockford, IL, USA) were then added at room temperature for 2 h. After five washes with DPBS, agarose bead immunoprecipitates were suspended in 1x NuPAGE LDS buffer (Invitrogen, boiled for 10 min, and run on SDS-PAGE followed by western blot, and transferred onto PVDF membranes. All PFT treatments were conducted by treating RBCs with 0.5 HU of PFT for 30 min at 37 °C before IP procedure. VLY-PYD4 and PLY-VLYD4 were added to RBCs at a concentration of 1 μg/ml.

Immunoblots. For phosphorylated RIP1 (p-RIP1) and RIP3 (p-RIP3) detection, blots were blocked/washed with 5% BSA in TBS. A rabbit mAb (100G7E, Cell Signaling Technology, Danvers, MA, USA) against phospho-Ser/Thr was used at 1:1000 to detect p-RIP1 and p-RIP3 as previously.11,20 For Band 3 or p-Syk detection, RBC lysates (5% (v/v)) were probed with anti-phospho Y21 Band 3 mAb (1:1000, AbCam, Cambridge, MA, USA) or anti-phospho Syk (Y525/526) (clone C87C1, 1:1000, Cell Signaling Technology) and blocked/washed with 5% BSA in TBS. All other blots were blocked/washed with 5% milk in DPBS. Total RIP1 was detected with anti-RIP mAb (G322-2, Becton Dickenson) at 1:1000. Total RIP3 was detected with polyclonal anti-RIP3 (ThermoScientific) at 1:1000. Total Band 3 was detected with anti-Band 3 mAb (Bil1-136, Sigma-Aldrich) at 1:1000. Total Syk was detected with polyclonal anti-Syk (Cell Signaling Technology) at 1:1000. FasL was detected with rabbit pAb against Fasl (ab15285, AbCam) at 1:250. Anti-mouse or anti-rabbit secondary horseradish peroxidase conjugates (1:1000, Thermo-Scientific) were used to detect primary antibodies. Western blots were developed with Lumi-Light substrate (Roche, Nutley, NJ, USA) for 5 min at room temperature and read in a FluorChem E imager (ProteinSimple, San Jose, CA, USA).

Phase-contrast microscopy. Human RBC suspensions (0.5% (v/v)) were treated with 0.2 HU of PFT or 1 μg/ml of anti-CD59 mAb (MEM-43, ThermoScientific)
and goat anti-mouse IgG (1:100, Jackson ImmunoResearch) for 15 min at room temperature. Unstained RBCs were viewed under bright-field using an Axio Observer.Z1 microscope (Zeiss, Thornwood, NY, USA) and an AxioCam MRm digital camera (Zeiss).

**FasL release assay.** FasL release assays were performed with 10% RBC suspensions. RBCs were treated with sub-hemolytic doses of PFTs or were treated with crosslinking mAbs against ICOS as described above for 1 h at 37 °C. RBCs were centrifuged and supernatants were run on SDS-PAGE and transferred onto PVDF for western blot analysis or were analyzed via ELISA (Fas ligand ELISA kit, AbCam).

**Eryptosis.** Hyperosmotic eryptosis was induced by 24 h incubation of RBCs (1%) in DPBS containing 950 mM sucrose at 37 °C. Calcium-induced eryptosis was achieved by incubation of RBCs (1%) with 1 mM exogenous CaCl2 for 24 h at 37 °C.

**Conflict of Interest**

The authors declare no conflict of interest.

1. LaRocca TJ, Stivison EA, Hod EA, Spitalnik SL, Cowan PJ, Randis TM et al. Human-specific bacterial pore-forming toxins induce programmed necrosis in erythrocytes. mBio 2014; 5: e01251–14.
2. Lang E, Qadri SM, Lang F. Killing me softly - suicidal erythrocyte death. Int J Biochem Cell Biol 2012; 44: 1236–1243.
3. Kondos SC, Hattaliad W, Yosokubonik L, Trapani JA, LA RH, Whistock JC et al. The structure and function of mammalian membrane-attack complex/perforin-like proteins. Tissue Antigens 2010; 76: 341–351.
4. Los FC, Randis TM, Aroian RV, Ratner AJ. Role of pore-forming toxins in bacterial infectious diseases. Microbiol Mol Biol Rev 2013; 77: 173–207.
5. Holler N, Zaru R, Micheau O, Thorne M, Attigheh A, Valaitt S et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2006; 7: 489–495.
6. Han J, Zhong CO, Zhang DW. Programmed necrosis: backup to and competitor with apoptosis in the immune system. Nat Immunol 2011; 12: 1143–1149.
7. Vandenabeele P, Galluzzi L, Vanden Bergh T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700–714.
8. Korchev YE, Bashford CL, Pedercelli C, Pederzolli CA, Morgan PJ, Andrew PW et al. A conserved tryptophan in pneumolysin is a determinant of the characteristics of channels formed by pneumolysin in cells and planar lipid bilayers. Biochim J 1998; 329: 571–577.
9. Jursch R, Hildebrand A, Hobom G, Trapani JA, Law RH, Whisstock JC et al. Histidine residues near the N terminus of staphylococcal alpha-toxin as reporters of regions that are critical for oligomerization and pore formation. Infect Immun 1994; 62: 2249–2256.
10. Ratner AJ, Hippe KR, Aguilar JL, Bender MH, Nelson AL, Weiser JN. Epithelial cells are sensitive detectors of bacterial pore-forming toxins. J Biol Chem 2006; 281: 12994–12998.
11. Marchlewicz BA, Duncan JL. Lysis of erythrocytes by a hemolysin produced by a group B Streptococcus sp. Infect Immun 1981; 34: 797–794.
12. Ford J. Red blood cell morphology. Int J Lab Hematol 2013; 35: 351–357.
13. Fern E, Giger K, Pantaleo A, Campanella E, Grey J, Ritchie K et al. Regulation of membrane-cytoskeletal interactions by tyrosine phosphorylation of erythrocyte band 3. Blood 2011; 117: 5998–6006.
14. Bordin L, D’Azzo G, Moni I, Dalla Vecchia F, Morel V. Functional link between phosphorylation state of membrane proteins and morphological changes of human erythrocytes. Biochem Biophys Res Commun 1995; 213: 249–257.
15. Reinhart WH, Sung LP, Sung KL, Bernstein SE, Chien S. Impaired echinocytic transformation of arkyte- and spectrin-deficient erythrocytes in mice. Am J Hematol 1988; 29: 195–200.
16. Anong WA, Franco T, Chu H, Weis TL, Devlin EE, Bodine DM et al. Adducin forms a bridge between the erythrocyte membrane and its cytoskeleton and regulates membrane cohesion. Blood 2009; 114: 1904–1912.
17. Martinez-Lorenzo MJ, Anel A, Gamen S, Monie n I, Lasierra P, Larrad L et al. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol 1999; 162: 1274–1281.
18. Andrews G, Rivelstor L, Castelli C, Huber V, Perso P, Dego P et al. Induction of lymphocyte apoptosis by tumor cell secretion of Fas-ligand-bearing microvesicles. J Exp Med 2002; 195: 1303–1316.
19. Voas M, Lettau M, Paulsen M, Janssen O. Posttranslational regulation of Fas ligand function. Cell Signal 2008; 6: 11.
20. Kimberley FC, Sivasanker B, Paul Morgan B. Alternative roles for CD59. Mol Immunol 2007; 44: 73–81.
21. Gillespie SH, Balakrishnan I. Pathogenesis of pneumococcal infection. J Med Microbiol 2000; 49: 1057–1067.
22. Tschopp J. Cholesterol-dependent cytolsins, a family of versatile pore-forming toxins. Infect Immun 2005; 73: 6190–6209.
23. Tschopp J. Ultrastructure of the membrane attack complex of complement. Heterogeneity of the complex caused by different degree of C9 polymerization. J Biol Chem 1984; 259: 7857–7863.
24. Matute-Bello G, Liles WC, Frevert CW, Dhanreddy S, Ballman K, Wong V et al. Blockade of the Fas/Fasl system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen. J Infect Dis 2005; 191: 596–606.
25. Dockrell DH, Lee M, Lynch DH, Read RC. Immune-mediated phagocytosis and killing of Streptococcus pneumoniae are associated with direct and bystander macrophage necroptosis. J Infect Dis 2001; 184: 713–722.
26. Murray EW, Robbins SM. Antibody cross-linking of the glycosylphosphatidylinositol-linked protein CD59 on hematopoietic cells induces signaling pathways resembling activation by complement. J Biol Chem 1998; 273: 25279–25284.
27. Gelber SE, Aguilar JL, Lewis KL, Ratner AJ. Functional and phylogenetic characterization of Vagnolysin, the human-specific cytolsin from Gardnerella vaginalis. J Bact 2008; 190: 3969–3983.
28. Rampersaud R, Planet PJ, Randis TM, Kulkarni R, Aguilar JL, Lehrer RI et al. Inerolysin, a cholesterol-dependent cytolsin produced by Lactobacillus iners. J Bact 2011; 193: 1034–1041.
29. Liu GY, Doran KS, Lawrence T, Turkson N, Puliti M, Tissi L et al. Sword and shield: linked group B streptococcal beta-hemolysin/cytolsin and cardenoloid pigment function to subvert host phagocyte defense. Proc Natl Acad Sci USA 2004; 101: 14491–14496.
30. Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-alpha-feed forward signaling. Cell 2011; 145: 92–103.